MM-151

N/A

Report date: 2022/11/25 17:30:35

Base Information

Drug NameMM-151
Drug Alias NameMM-151
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMerrimack Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMerrimack Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksN/A